Cell>Point

About Cell>Point

Cell>Point was a biotechnology firm established in 2001 and headquartered in Centennial, Colorado. The company concentrated on developing intra-nuclear molecular imaging agents and therapeutic compounds. Its primary market focus was on significant health sectors, including oncology, cardiology, and neurology, with applications for conditions like stroke and ischemic-based diseases.

The company's core technology centered on chelation-based metabolic imaging. A key product in its pipeline was a technetium-99m labeled glucosamine compound, specifically technetium-99m-labeled glucosamine (Tc-99m EC-G). This agent was designed for use in Single-Photon Emission Computed Tomography (SPECT/CT) to diagnose, stage, and monitor cancerous tumors, particularly in lung cancer. The objective was to provide healthcare professionals with advanced tools for more effective patient treatment. The U.S. Food and Drug Administration (FDA) had agreed to a special protocol assessment for a Phase III trial of this agent for lung cancer applications.

As a privately held, venture capital-backed entity, Cell>Point participated in several funding rounds, including a Later Stage VC round in June 2021. However, public records indicate that the company is now out of business as of January 2024.